Multiple roles of extracellular fibroblast growth factors in lung cancer cells

Suzuki,Takahiro; Yasuda,Hiroyuki; Funaishi,Koji; Arai,Daisuke; Ishioka,Kota; Ohgino,Keiko; Tani,Tetsuo; Hamamoto,Junko; Ohashi,Ayano; Naoki,Katsuhiko; Betsuyaku,Tomoko; Soejima,Kenzo

doi:10.3892/ijo.2014.2718

Multiple roles of extracellular fibroblast growth factors in lung cancer cells

Authors:
- Takahiro Suzuki
- Hiroyuki Yasuda
- Koji Funaishi
- Daisuke Arai
- Kota Ishioka
- Keiko Ohgino
- Tetsuo Tani
- Junko Hamamoto
- Ayano Ohashi
- Katsuhiko Naoki
- Tomoko Betsuyaku
- Kenzo Soejima
View Affiliations

Affiliations: Keio University School of Medicine, Tokyo 160-8582, Japan, Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan, Keio Cancer Center, Keio University Hospital, Shinjuku-ku, Tokyo 160-8582, Japan
Published online on: October 21, 2014 https://doi.org/10.3892/ijo.2014.2718
Pages: 423-429

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer cells are surrounded by the extracellular fluid, matrix, and stroma cells. Little is known about how extracellular components such as growth factor ligands affect the biology of lung cancer cells. The objective of this study was to determine whether extracellular fibroblast growth factors (FGFs) can affect the biology of lung cancer cells and to understand how extracellular FGFs affect the biology of lung cancer cells, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. Out of the 23 reported FGFs, we focused on FGF2, FGF9 and FGF10. We examined the effect of FGFs on proliferation, treatment sensitivity, and apoptosis of NSCLC (PC9) and SCLC (H69, H82 and H146) cells in vitro. To determine which FGF was the most clinically relevant, we also examined FGF2 and FGF9 concentrations in the serum of patients with lung cancer. We found that extracellular FGFs can affect proliferation, treatment sensitivity, and apoptosis of lung cancer cells in a cell-specific manner. Our results indicate that extracellular FGFs affect the biology of lung cancer cells through multiple functions.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
3	Imielinski M, Berger AH, Hammerman PS, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
4	Wistuba II, Gazdar AF and Minna JD: Molecular genetics of small cell lung carcinoma. Semin Oncol. 28:3–13. 2001. View Article : Google Scholar : PubMed/NCBI
5	Peifer M, Fernandez-Cuesta L, Sos ML, et al: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 44:1104–1110. 2012. View Article : Google Scholar : PubMed/NCBI
6	Weir BA, Woo MS, Getz G, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature. 450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
7	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
8	Yasuda H, Kobayashi S and Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 13:e23–31. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yasuda H, Park E, Yun CH, et al: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 5:216ra1772013. View Article : Google Scholar : PubMed/NCBI
10	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
11	Choi YL, Takeuchi K, Soda M, et al: Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68:4971–4976. 2008. View Article : Google Scholar : PubMed/NCBI
12	Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2:62ra932010. View Article : Google Scholar : PubMed/NCBI
13	Costa DB, Halmos B, Kumar A, et al: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4:1669–1680. 2007. View Article : Google Scholar : PubMed/NCBI
14	Yasuda H, de Figueiredo-Pontes LL, Kobayashi S and Costa DB: Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 7:1086–1090. 2012. View Article : Google Scholar
15	Liao RG, Jung J, Tchaicha J, et al: Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73:5195–5205. 2013. View Article : Google Scholar : PubMed/NCBI
16	Dutt A, Ramos AH, Hammerman PS, et al: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 6:e203512011. View Article : Google Scholar : PubMed/NCBI
17	Pardo OE, Latigo J, Jeffery RE, et al: The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 69:8645–8651. 2009. View Article : Google Scholar : PubMed/NCBI
18	Dieci MV, Arnedos M, Andre F and Soria JC: Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 3:264–279. 2013. View Article : Google Scholar : PubMed/NCBI
19	Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
20	Donnem T, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol. 4:578–585. 2009. View Article : Google Scholar : PubMed/NCBI
21	Rades D, Seibold ND, Gebhard MP, Noack F, Bruchhage KL and Schild SE: Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol. 190:68–74. 2014. View Article : Google Scholar : PubMed/NCBI
22	Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
23	Nomura S, Yoshitomi H, Takano S, et al: FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br J Cancer. 99:305–313. 2008. View Article : Google Scholar : PubMed/NCBI
24	Ohgino K, Soejima K, Yasuda H, et al: Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer. 83:90–96. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yin Y, Betsuyaku T, Garbow JR, Miao J, Govindan R and Ornitz DM: Rapid induction of lung adenocarcinoma by fibro-blast growth factor 9 signaling through FGF receptor 3. Cancer Res. 73:5730–5741. 2013. View Article : Google Scholar : PubMed/NCBI
26	Terai H, Soejima K, Yasuda H, et al: Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 11:759–767. 2013. View Article : Google Scholar : PubMed/NCBI
27	Lefevre G, Babchia N, Calipel A, et al: Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest Ophthalmol Vis Sci. 50:1047–1057. 2009. View Article : Google Scholar : PubMed/NCBI
28	Fillmore CM, Gupta PB, Rudnick JA, et al: Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA. 107:21737–21742. 2010. View Article : Google Scholar : PubMed/NCBI